[Investigation of therapeutic and protective effect of Reaferon-ES Lipint on mice infected with avian influenza virus (subtype H5N1)].
The efficacy of the therapeutic, prophylactic and urgent prophylactic schemes for the use of Reaferon-ES lipint, a liposomal human recombinant alpha-interferon for oral use, was studied on mice infected with the avian influenza virus. Strain A/Chicken/Kurgan /05/2005 (subtype H5N1) of the avian influenza virus showed high virulence with respect to mice ICR. Theoretically-based calculations allowed to design an optimal therapeutic and prophylactic dose of the drug for the mice (1000 units/animal). It was observed that only after prophylactic use of Reaferon-ES lipint it was effective in protection of the mice infected with 10 LD50 of the avian influenza virus (A/Chicken/Kurgan/05/2005, H5N1). The protection coefficient was 0.35. Under such conditions the drug efficacy was comparable with that of Tamiflu. Therefore, Reaferon-ES lipint could be recommended for prophylaxis of the infection due not only to the season strains of the influenza virus, but also to the strains of the avian influenza virus.
Demina
O K
OK
Sergeev
A A
AA
Agafonov
A P
AP
Shikov
A N
AN
Sementsova
A O
AO
Sergeev
A A
AA
Sergeev
A N
AN
Drozdov
I G
IG
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D053124:Influenza A Virus, H5N1 Subtype / Q000472:pathogenicity; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009976:Orthomyxoviridae Infections / Q000188:drug therapy* / Q000517:prevention & control* / Q000821:virology; D011994:Recombinant Proteins
D000998:Antiviral Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins